Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...
Kenvue spun off from Johnson & Johnson (JNJ) in 2023. To watch more expert insights and analysis on the latest market ...